Chair’s Address to the Annual General Meeting

28 November 2017

Coming from the background of an ethical pharmaceutical company I had some misgivings 15 years ago of joining the board of a company with a ‘tanning’ drug. Here we are today, a genuine biopharmaceutical company having posted revenues of AUD$17.3m on a single drug used to treat an unusual orphan disorder.